News: RAP Resapp Health Announces Increased Scheme Consideration From Pfizer

June 14 (Reuters) - Resapp Health Ltd (RAP) :

• INCREASED SCHEME CONSIDERATION FROM PFIZER
• INCREASE SCHEME CONSIDERATION TO A$0.207 PER SHARE FROM A$0.115 PER SHARE IN CASH
• CO, PFIZER AGREED TO INCREASE CONSIDERATION TO A$0.146/SHARE IN CASH IF CONFIRMATORY DATA READOUT CONDITION NOT SATISFIED
• BOARD UNANIMOUSLY RECOMMENDS THAT RESAPP SHAREHOLDERS VOTE IN FAVOUR OF REVISED SCHEME
• WILL INCREASE SCHEME CONSIDERATION TO A$0.207 PER SHARE IN CASH, IF CONFIRMATORY DATA READOUT CONDITION IS SATISFIED